Brad King has been named a Law360 “Rising Star” for Life Sciences—one of five Sullivan & Cromwell partners selected in 2023 from more than 1,300 submissions. Brad, a partner in S&C’s Mergers & Acquisitions Group, has significant experience advising companies in major life sciences deals.
In the largest ever all-cash takeover in the biopharmaceutical industry, and the largest-ever acquisition of a pre-profitability company in any industry, Brad is advising Seagen in its $43 billion pending acquisition by Pfizer. Last year, Brad advised Verily, the life sciences subsidiary of Alphabet (Google’s parent company), in two deals to further its mission to advance data-driven healthcare—obtaining sole ownership of Granular Insurance Company, a precision risk coverage provider, and securing a $1 billion investment round led by Alphabet.
When asked about what motivates him, Brad said advising on M&A deals that will help his clients achieve better outcomes for healthcare patients is a “huge motivator.” “I think we're helping our clients achieve things strategically, ” he said. “It's an added benefit that these deals are also so helpful to patients and are bettering healthcare that people receive.”
Read Brad’s profile.